EMERYVILLE, Calif.—NovaBay Pharmaceuticals (NYSE MKT: NBY) reported total net sales of $1.2 million for the third quarter ending Sept. 30, 2015, up from $152,000 for the third quarter of 2014. The increase was due to growing sales of Avenova, which was commercially launched in August 2014, partially offset by a decrease in collaboration revenue, according to the company.

Product revenue, including sales of Avenova and NeutroPhase, for the third quarter of 2015 reached $1.1 million, up from $90,000 for the third quarter of 2014. Other revenue for the third quarter of 2015 was $64,000, compared with $62,000 for the prior-year period. Gross margin as a percentage of total net sales increased to 78 percent for the third quarter of 2015, up from 72 percent for the prior-year period.

For the nine months ended Sept. 30, 2015, total net sales increased by $2.2 million to $2.7 million from $563,000 in the first nine months of 2014. Product revenue for the first nine months of 2015 reached $2.6 million compared with $299,000 for the nine months ended Sept. 30, 2014. Other revenue for the first nine months of 2015 was $187,000, compared with $264,000 for the prior-year period. Gross margin as a percentage of total sales increased to 76 percent from 66 percent for the first nine months of 2014.